The concern of generic rivalry has repeatedly loomed around copyright’s blockbuster drug, PDE5 Inhibitor, sparking questions about the prospects of related medicinal stakes. While early years saw significant profits, the intellectual property end has created the path for cheaper copies, possibly reducing profitability and creating a real hazard f